CAS Number 1445583-51-6 ChemSpider 29763706 Formula C21H23FN4O2 | PubChem CID 70969086 UNII 05235E1S2O Molar mass 382.43 g/mol | |
 | ||
Legal status CA: Schedule II
DE: Anlage II (Prohibited) | ||
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
Side effects
One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication.